With two weeks to go, confusion surrounds hep C drug advice

A LACK of clarity surrounds prescribing guidelines for new-generation hepatitis C drugs that are set to be PBS authority-listed in two weeks.

The guidelines give all GPs the ability to prescribe the three new direct-acting antivirals (DAAs) “in consultation” with specialists and state patient eligibility criteria.

Sydney GP Dr David Baker, who has a special interest in hepatitis C, is concerned GPs, whether experienced or not, won’t know what information needs to be supplied to the PBS, liver clinics or specialist hepatologists, gastroenterologists and